oru.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Erlandsson, Ann
Publications (7 of 7) Show all publications
Davidsson, S., Sundqvist, P., Giunchi, F., Erlandsson, A., Fiorentiono, M. & Carlsson, J. (2019). M2 macrophages and regulatory T cells as prognostic markers in renal cell carcinoma. In: : . Paper presented at Keystone Symposia Conference 2109: Cancer metastasis: The role of metabolism, immunity and the microenvironment, Florens, Italy, March 15—19, 2019.
Open this publication in new window or tab >>M2 macrophages and regulatory T cells as prognostic markers in renal cell carcinoma
Show others...
2019 (English)Conference paper, Oral presentation with published abstract (Refereed)
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-73842 (URN)
Conference
Keystone Symposia Conference 2109: Cancer metastasis: The role of metabolism, immunity and the microenvironment, Florens, Italy, March 15—19, 2019
Available from: 2019-04-17 Created: 2019-04-17 Last updated: 2019-04-17Bibliographically approved
Erlandsson, A., Carlsson, J., Lundholm, M., Fält, A., Andersson, S.-O., Andrén, O. & Davidsson, S. (2019). M2 macrophages and regulatory T cells in lethal prostate cancer. The Prostate, 79(4), 363-369
Open this publication in new window or tab >>M2 macrophages and regulatory T cells in lethal prostate cancer
Show others...
2019 (English)In: The Prostate, ISSN 0270-4137, E-ISSN 1097-0045, Vol. 79, no 4, p. 363-369Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Prostate cancer (PCa) is one of the most frequently diagnosed cancers in the world. Emerging evidence suggests that inflammatory cells such as M2 macrophages and regulatory T cells (Tregs) can contribute to cancer progression by suppressing the anti‐tumor immune response. This study investigated the number of CD163‐positive M2 macrophages in PCa tissue. It also investigated the correlation and interaction of M2 macrophages and Tregs.

METHODS: were assessed using Spearman's rank-order correlation and a likelihood test, respectively. Logistic regression was used to estimate odds ratios (ORs) for lethal PCa and macrophage counts.

RESULTS: showed a significant correlation (P < 0.001) but no interactions. The OR for lethal PCa was 1.93 (95%CI: 1.23-3.03) for men with high numbers of M2 macrophages. Also for cases with uncertain outcome (GS categories 3 + 4 and 4 + 3) high numbers of M2 macrophages does predict a poorer prognosis.

CONCLUSIONS: Our data showed that men with high numbers of M2 macrophages in the prostate tumor environment had increased odds of dying of PCa. It is possible that M2 macrophages, together with other suppressor cells such as Tregs , promote an immunosuppressive environment.

Place, publisher, year, edition, pages
John Wiley & Sons, 2019
Keywords
CD163, FOXP3, TAMs, Tregs
National Category
Urology and Nephrology Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-70404 (URN)10.1002/pros.23742 (DOI)000456214000004 ()30500076 (PubMedID)2-s2.0-85057833977 (Scopus ID)
Available from: 2018-12-03 Created: 2018-12-03 Last updated: 2019-02-05Bibliographically approved
Matikas, A., Lövrot, J., Ramberg, A., Eriksson, M., Lindsten, T., Lekberg, T., . . . Foukakis, T. (2018). Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. Oncoimmunology, 7(9), Article ID e1466017.
Open this publication in new window or tab >>Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
Show others...
2018 (English)In: Oncoimmunology, ISSN 2162-4011, E-ISSN 2162-402X, Vol. 7, no 9, article id e1466017Article in journal (Refereed) Published
Abstract [en]

Gene expression (GE) signatures and Tumor Infiltrating Lymphocytes (TIL) enumeration are predictive for response to neoadjuvant chemotherapy in HR- and in HER2+ breast cancer, but data are conflicting in HR+/HER2- disease. This study aimed to explore their predictive value in this subset, measured both at baseline and after short exposure to chemotherapy. Specifically, the PROMIX phase 2 trial enrolled patients with locally advanced HER2- BC to receive six cycles of epirubicin and docetaxel, plus bevacizumab during cycles 3-6. Patients underwent tumor biopsies at baseline and after cycle 2 for GE profiling and enumeration of TIL, FOXP3+ T-cells and CD163+ macrophages. An immune related gene module and the quantification of the immune infiltrate were analyzed for association with pathologic complete response (pCR), decrease in tumor size and disease-free survival (DFS). Of the 150 patients enrolled in PROMIX, 113 were HR+/HER2-. Baseline GE and immune cell enumeration data were available from 71 patients, while data after 2 cycles of chemotherapy were available from 41. At baseline, only GE was statistically significantly associated with higher pCR rates (OR 2.29, 95% CI 1.05 - 5.38, p = 0.037) and decrease in tumor size (r = 0.25, p = 0.047). In contrast, longitudinal data indicate that both GE (r = 0.54, p<0.001) and TIL abundance (p = 0.009) are stronger predictors for the reduction of tumor size, while low FOXP3+ was statistically significantly associated with an improved DFS (p = 0.027). In conclusion, GE analysis, TIL and FOXP3+ enumeration after short-term exposure to chemotherapy carry important predictive information in HR+/HER2- breast cancer at the neoadjuvant setting.

Place, publisher, year, edition, pages
Taylor & Francis, 2018
Keywords
biomarker, breast cancer, gene expression, predictive, tumor infiltrating lymphocytes
National Category
Cancer and Oncology Immunology in the medical area
Identifiers
urn:nbn:se:oru:diva-69011 (URN)10.1080/2162402X.2018.1466017 (DOI)000443993100004 ()30228933 (PubMedID)2-s2.0-85050943278 (Scopus ID)
Funder
Swedish Cancer Society, CAN 2015/713Stockholm County CouncilBioCARE - Biomarkers in Cancer Medicine Improving Health Care Education and Innovation
Note

Funding Agencies:

European Society for Medical Oncology Georges Mathe Translational Research Fellowship  

Hellenic Society of Medical Oncology 

Cancer Society in Stockholm  154132 

Breast Cancer Theme Center (BRECT) at Karolinska Institutet

Roche Sweden AB  

Available from: 2018-09-25 Created: 2018-09-25 Last updated: 2018-09-25Bibliographically approved
Erlandsson, A., Carlsson, J., Andersson, S.-O., Vyas, C., Wikström, P., Andrén, O., . . . Rider, J. R. (2018). High inducible nitric oxide synthase in prostate tumor epithelium is associated with lethal prostate cancer. Scandinavian journal of urology, 52(2), 129-133
Open this publication in new window or tab >>High inducible nitric oxide synthase in prostate tumor epithelium is associated with lethal prostate cancer
Show others...
2018 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 52, no 2, p. 129-133Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: The aim of this study was to investigate the role of inducible nitric oxide synthase (iNOS) in lethal prostate cancer (PCa) by studying the iNOS immunoreactivity in tumor tissue from men diagnosed with localized PCa.

MATERIALS AND METHODS: This study is nested within a cohort of men diagnosed with incidental PCa undergoing transurethral resection of the prostate (the Swedish Watchful Waiting Cohort). To investigate molecular determinants of lethal PCa, men who died from PCa (n = 132) were selected as cases; controls (n = 168) comprised men with PCa who survived for at least 10 years without dying from PCa during follow-up. The immunoreactivity of iNOS in prostate tumor epithelial cells and in cells of the surrounding stroma was scored as low/negative, moderate or high. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for lethal PCa according to iNOS category.

RESULTS: There was no association between iNOS immunoreactivity in stroma and lethal disease. However, when comparing high versus low/negative iNOS immunoreactivity in epithelial cells, the OR for lethal PCa was 3.80 (95% CI 1.45-9.97).

CONCLUSION: Patients with localized PCa have variable outcomes, especially those with moderately differentiated tumors. Identifying factors associated with long-term PCa outcomes can elucidate PCa tumor biology and identify new candidate prognostic markers. These findings support the hypothesis that high iNOS in tumor epithelium of the prostate is associated with lethal disease.

Place, publisher, year, edition, pages
Informa Healthcare, 2018
Keywords
Inducible nitric oxide synthase, iNOS, nitric oxide, prognostic marker, prostate cancer
National Category
Urology and Nephrology Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-64111 (URN)10.1080/21681805.2017.1421261 (DOI)000446242100009 ()29307261 (PubMedID)2-s2.0-85041130976 (Scopus ID)
Note

Funding Agencies:

Örebro County Council Research Committee  

Foundation for Medical Research at Örebro University Hospital, Sweden  OLL-577581  OLL-488741 

Available from: 2018-01-12 Created: 2018-01-12 Last updated: 2018-10-16Bibliographically approved
Lindsten, T., Hedbrant, A., Ramberg, A., Wijkander, J., Solterbeck, A., Eriksson, M., . . . Erlandsson, A. (2017). Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2. International Journal of Oncology, 51(1), 104-114
Open this publication in new window or tab >>Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2
Show others...
2017 (English)In: International Journal of Oncology, ISSN 1019-6439, Vol. 51, no 1, p. 104-114Article in journal (Refereed) Published
Abstract [en]

Malignant tumors, including breast cancers, are frequently infiltrated with innate immune cells and tumor-associated macrophages (TAMs) represent the major inflammatory component in stroma of many tumors. In this study, we examined the immunoreactivity of the macrophage markers CD68 and CD163 as well as the hormone receptors estrogen receptor alpha (ER alpha), progesterone receptor (PR), estrogen receptor beta 1 (ER beta 1), human epidermal growth factor receptor 2 (HER-2), matrix metalloproteinase 9 (MMP-9), urokinase-type plasminogen activator receptor (uPAR) and the proliferations marker Ki67 in 17 breast cancer biopsies. The quantitative score for CD68(+) and CD163(+) strongly indicate M2 phenotype dominance in the currently investigated biopsies. We found that an increasing level of macrophages was negatively associated with ER alpha or PR, whereas a positive association was observed for Ki-67 or uPAR. No significant association could be seen between the level of macrophage and HER-2, ER beta 1 or MMP-9 expression. Effect of conditioned media (CM) generated from cultured human M1 and M2 macrophage phenotypes were investigated on the proliferation and expression of selected markers in the T47D breast cancer cell line. We found that in contrast to the in vivo situation, in particularly the CM from M1 macrophages decreased the growth and Ki67 expression in T47D, and significantly increased ER beta 1 mRNA levels. Moreover, in accordance to the in vivo situation the CM from the macrophages decreased the expression of ER alpha protein as well as ER alpha or PR mRNA. In conclusion our results show that macrophages alone have the capability to decrease the tumor cell expression of ER alpha and PR in vitro. In the tumor environment in vivo macrophages also contribute to an increase in tumor cell expression of uPAR and Ki67, suggesting that macrophages are involved in impairing the prognosis for breast cancer patients.

Place, publisher, year, edition, pages
Spandidos Publications, 2017
Keywords
breast cancer, breast cancer cell line, T47D, estrogen receptors, progesterone receptor, M1 macrophages, M2 macrophages, urokinase-type plasminogen activator receptor
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-58940 (URN)10.3892/ijo.2017.3996 (DOI)000403994300009 ()28498427 (PubMedID)2-s2.0-85020544220 (Scopus ID)
Note

Funding Agencies:

County Council of Värmland  

Karlstad University  

Örebro University 

Available from: 2017-08-18 Created: 2017-08-18 Last updated: 2019-04-29Bibliographically approved
Matikas, A., Lovrot, J., Ramberg, A., Eriksson, M., Lindsten, T., Lekberg, T., . . . Foukakis, T. (2017). Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer. Paper presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, September 8-12, 2017. Annals of Oncology, 28(Suppl. 5), Article ID 219P.
Open this publication in new window or tab >>Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
Show others...
2017 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 28, no Suppl. 5, article id 219PArticle in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Oxford University Press, 2017
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:oru:diva-61639 (URN)000411324000209 ()
Conference
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, September 8-12, 2017
Funder
Swedish Cancer Society
Note

Funding Agencies:

Clinical Research within the National Health Service  

Roche Sweden AB  

BioCARE 

Available from: 2017-10-18 Created: 2017-10-18 Last updated: 2018-08-06Bibliographically approved
Rider, J. R., Erlandsson, A., Vyas, C., Davidsson, S., Carlsson, J., Andersson, S.-O. & Andren, O. (2017). iNOS expression and lethal prostate cancer in patients with localized disease. Paper presented at AACR International Conference: New Frontiers in Cancer Research, Cape Town, South Africa, January 18-22, 2017. Cancer Research (22S), Article ID B26.
Open this publication in new window or tab >>iNOS expression and lethal prostate cancer in patients with localized disease
Show others...
2017 (English)In: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, no 22S, article id B26Article in journal, Meeting abstract (Refereed) Published
Abstract [en]

Inducible nitric oxide synthase (iNOS) has demonstrated both tumor-promoting and tumor-inhibiting effects in prostate cancer. However, the relationship between iNOS protein expression and long-term prostate cancer outcomes is unclear. We evaluated iNOS expression in tumor epithelia and stroma in 300 men with localized tumors diagnosed incidentally by transurethral resection of the prostate (TURP) in Sweden. In this extreme case-control design, cases (N=132) died of prostate cancer and controls (N=168) survived at least 8 years following diagnosis without death from prostate cancer or a competing cause. Immunohistochemistry was undertaken with a polyclonal rabbit anti-human NOS2 antibody (Abcam) and the Ventana (Roche) semi-automated staining system. Two observers individually scored the staining according to intensity and number of positive cells from 0-3. The median value across cores in each patient were then categorized as <1, >1-<2, and >2, separately for epithelial and stromal compartments. Odds ratios for lethal prostate cancer were estimated with logistic regression controlling for the matching factors (age, calendar year of diagnosis), as well as tumor stage, Gleason score, and percent tumor. iNOS was expressed by stromal-associated M1 macrophages and fibroblasts, as well as tumor cells. Gleason score was positively associated with both stromal and epithelial iNOS staining. In the stroma, there was no statistically significant association between iNOS expression and lethal prostate cancer after adjustment for clinical covariates. However, the odds of lethal prostate cancer increased with tumor expression of iNOS in the fully adjusted model. Compared to patients with the lowest category of iNOS expression, the odds ratios for lethal prostate cancer were 2.96 (95% CI: 1.26-6.96) for patients in the second category and 3.80 (95% CI: 1.45-9.97) for patients in the top category. These results suggest that iNOS may help to identify patients with aggressive prostate cancer at the time of diagnosis, or may be a therapeutic target. Given previously reported in vitro data suggesting that iNOS promotes proliferation of androgen-independent prostate tumors, future analyses will investigate association between iNOS expression and time to castration-resistant prostate cancer in this patient population.

Place, publisher, year, edition, pages
American Association for Cancer Research, 2017
National Category
Cancer and Oncology Urology and Nephrology
Identifiers
urn:nbn:se:oru:diva-69409 (URN)10.1158/1538-7445.NEWFRONT17-B26 (DOI)000468801300049 ()
Conference
AACR International Conference: New Frontiers in Cancer Research, Cape Town, South Africa, January 18-22, 2017
Available from: 2018-10-08 Created: 2018-10-08 Last updated: 2019-06-18Bibliographically approved
Organisations

Search in DiVA

Show all publications